BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. [electronic resource]
Producer: 20060131Description: 943-52 p. digitalISSN:- 0937-941X
- Administration, Oral
- Aged
- Alendronate -- administration & dosage
- Bone Density -- drug effects
- Bone Density Conservation Agents -- administration & dosage
- Bone Resorption -- prevention & control
- Drug Combinations
- Drug Therapy, Combination
- Estrogens, Conjugated (USP) -- administration & dosage
- Female
- Genotype
- Hormone Replacement Therapy -- adverse effects
- Humans
- Medroxyprogesterone Acetate -- administration & dosage
- Middle Aged
- Osteoporosis, Postmenopausal -- drug therapy
- Prospective Studies
- Raloxifene Hydrochloride -- administration & dosage
- Receptors, Calcitriol -- genetics
- Selective Estrogen Receptor Modulators -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.